Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice. The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer

Trial Details

NCT ID

NCT06860529

Phase

PHASE2

Sponsor

Henan Cancer Hospital

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• Serplulimab
• Epirubicin
• Albumin Paclitaxel

Locations (sample)

• Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

• Patients must meet all of the following criteria to be eligible:
• Age: ≥18 years old.
• Clinical-pathological confirmation:
• cT2-cT4 breast cancer, or cT1c with axillary lymph node metastasis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →